lung carcinoma occurs patients chronic lung disease emphysema pulmonary fibrosis diseases characterized dramatic alterations content composition lung extracellular matrix believe altered matrix ability promote lung carcinoma cell growth extracellular matrix molecule shown altered lung diseases fibronectin fn previously reported increased growth survival cell lung carcinoma nsclc cells exposed fn fn serve factor nsclc represents novel target strategies end studied effects ppargamma ligands rosiglitazone brl49653 troglitazone fn expression nsclc cells able inhibit fn gene transcription inhibition fn expression brl49653 troglitazone prevented specific ppargamma antagonist ppargamma small interfering rna working fn deletion mutated promoter constructs region bp downstream transcriptional start site promoter involved ppargamma ligand inhibition ppargamma ligands diminished phosphorylation creb diminished sp1 nuclear protein expression prevented binding transcription factors cre sp1 sites respectively fn promoter summary results demonstrate ppargamma ligands inhibit fn gene expression nsclc cells pathways affect creb sp1 tobacco related asbestos related non small anti cancer 15d pgj2 15d pgj2 gw NUMBER NUMBER NUMBER ppargamma dependent independent mitogen survival